Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker for Alport Syndrome: An International, Multicenter, Observational, Longitudinal Protocol

NCT02718027 is registered in ClinicalTrials.gov with CENTOGENE GmbH Rostock as lead sponsor.

NCT NCT02718027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02718027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker for Alport Syndrome: An International, Multicenter, Observational, Longitudinal Protocol
Lead sponsor
CENTOGENE GmbH Rostock
Phase
Observational
Overall status
Terminated
Start date
August 20, 2018
Completion date
December 31, 2022
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hematuria-nephropathy-deafness syndrome, nephritis, hereditary